Galectin-3 (Gal-3) is a 29-to 35-kDa protein, member of a β-galactoside-binding lectin family expressed in fibroblasts, 13 endothelial cells, 14 and inflammatory cells, 15 which seems to be involved in most models of injury. We and others have observed in clinical studies increased levels of Gal-3 in patients with heart failure, which were correlated with serum ECM markers. 16 In addition, Gal-3 was recently reported to have a prognostic value in patients with coronary artery disease, possibly related to its role in plaque destabilization. 17 Several inhibitors of Gal-3 have been described, such as the modified citrus pectin (MCP; a complex water soluble indigestible polysaccharide riche in β-galactose) being able to block the lectin's activity. 18 We have recently demonstrated that Gal-3 mediates the vascular remodeling and the cardiac fibrosis induced by aldosterone. 19, 20 In addition, Azibani et al 21 have demonstrated that hyperaldosteronism worsens hypertension-induced fibrosis through an increase of inflammatory molecules such as Gal-3. However, the precise mechanism responsible for aldosterone-induced cardiac inflammation and the role of Gal-3 in the inflammation induced by aldosterone are still unclear. We aimed to evaluate the effects of Figure 1 . Pharmacological inhibition of galectin-3 (Gal-3)-blocked aldosterone (Aldo)-salt-induced cardiac inflammation. Effects of spironolactone (Spiro) or modified citrus pectin (MCP) cotreatment on plasma (A) and cardiac (B) inflammatory markers in Aldosalt-treated rats. C, Representative microphotographs and quantification of myocardial sections stained for chemokine ligand 2 (CCL2), osteopontin (OPN), and CD68. D, Matrix metalloprotease-2 (MMP-2), MMP-9, and MMP-13 activities in Aldo-salt-treated rats in the presence or absence of Spiro or MCP. All conditions were performed at least in triplicate. Histogram bars represent the mean±SD of each group of animals (control group, n=10; Aldo-salt-treated rats, n=10; Aldo-salt plus Spiro-treated rats, n=10; and Aldo-salt plus MCP-treated rats, n=9) in arbitrary units or as a percentage of staining normalized to hypoxanthine-guanine phosphoribosyltransferase (HPRT) for cDNA. Magnification, ×40. *P<0.05 vs control; †P<0.05 vs Aldo-salt. CRP indicates C-reactive protein; IL, interleukin; and TNF-α, tumor necrosis factor-α.
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Gal-3 inhibition on cardiac inflammation and fibrosis in 3 different animal models of hyperaldosteronism: (1) hypertensive rat model induced by aldosterone-salt treatment, (2) SHR, and (3) normotensive wild-type (WT) and Gal-3 knockout mice treated with aldosterone without salt. In addition, we evaluate the effects of Gal-3 inhibition on cardiac inflammation and fibrosis mediators in human cardiac fibroblasts.
Methods
Detailed methods are available in the online-only Data Supplement.
Animals
Adult male Wistar rats were treated for 3 weeks with vehicle (n=10), aldosterone-salt (Sigma, 1 mg/kg per day diluted in sunflower oil and administered by subcutaneous injection and 1% NaCl as drinking water; n=10), aldosterone-salt plus spironolactone (Sigma, 200 mg/ kg per day; n=10), aldosterone-salt plus Gal-3 activity inhibitor, MCP (Enconugenics, 100 mg/kg per day; n=9), spironolactone (n=7), or MCP (n=5) alone. 20 Male normotensive Wystar-Kyoto (n=8) and SHR (n=16) were obtained from Harlan Ibérica. Half of the animals of SHR group received MCP (100 mg/kg per day) for 6 weeks in the drinking water.
For the Gal-3 knockout model, adult male C57BJ6 WT mice and Gal-3 knockout mice 22 were infused with aldosterone (1 mg/kg per day, osmotic minipump) or vehicle (n=7, each group) for 3 weeks.
The investigation was performed in accordance with the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (publication number, 82-23, revised in 1996). Body weight was measured once a week. Food and water intakes were determined throughout the experimental period. Systolic BP was estimated basally, at midstudy, and end-of-study through use of a tail-cuff plethysmograph (Narco Bio-Systems) in unrestrained animals. In all experimental models, blood and urines were collected, and hemodynamic parameters were evaluated.
Cell Culture
Human cardiac fibroblasts were obtained from Promocell and maintained in medium fibroblasts media 3. Cells were cultured according to the manufacturer's instructions. Cells were used between passages 5 and 7. Cells were stimulated with aldosterone (10 -8 mol/L; Sigma), Gal-3 (10 -8 mol/L; R&D Systems), and spironolactone (10 −6 mol/L; Sigma) for 6 hours for mRNA determinations and for 24 hours for protein analysis. The doses were chosen based on previous studies.
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Statistical Analyses
Data are expressed as mean±SD. Normality of distributions was verified by means of the Kolmogorov-Smirnov test. Data were analyzed using a 1-way ANOVA, followed by a Newman-Keuls test to assess specific differences among groups or conditions using GraphPad Software Inc. The predetermined significance level was P<0.05.
Results
Gal-3 Inhibition Improved Cardiac Inflammation and Fibrosis in 3 Experimental Models of Hyperaldosteronism
We investigated whether Gal-3 could be involved in cardiac inflammation additionally of fibrosis in 3 animal models in which aldosterone levels were abnormally increased. First, the effects of the pharmacological inhibition of Gal-3 with MCP in hypertensive aldosterone-salt-treated rats were analyzed. Then, the effect of Gal-3 blockade was studied in SHR. Finally, normotensive Gal-3 knockout mice were challenged with aldosterone without salt to avoid an increase in BP and its potential confounding effects.
We previously showed that aldosterone-salt treatment induced an increase in BP, cardiac fibrosis (assessed by collagen and transforming growth factor-β mRNA and protein expression), and Gal-3 expression (P<0.05). All these effects were prevented (P<0.05) by cotreatment with spironolactone or MCP. 20 Aldosterone-salt treatment induced an increase in C-reactive protein (7.0-fold; P<0.05) and tumor necrosis factor-α (3.0-fold; P<0.05) without modification in interleukin-1β (IL-1β) plasma levels, effects that were blocked by spironolactone or MCP cotreatment (P<0.05; Figure 1A ). Figure 1B ). This inflammatory response was characterized by CCL2, osteopontin, and macrophage infiltration in myocardium as shown in the representative pictures immunostained for proinflammatory markers ( Figure 1C ). Cotreatment with spironolactone or MCP abolished (P<0.05) all of modifications in proinflammatory molecules induced by aldosteronesalt treatment. Strong and positive correlations were found between Gal-3 and osteopontin at mRNA and protein levels ( Table 1) . No modifications were found between any group in MMP-2, MMP-9, and MMP-13 activities ( Figure 1D ). Spironolactone or MCP alone did not exert modifications in any of the parameters studied (data not shown). In the second hypertensive animal model, SHR rats presented an increase in systolic BP when compared with control rats (Table 2) . At cardiac level, hypertensive animals showed cardiac hypertrophy presenting an increase in relative heart weight and myocyte size ( Table 2 ). The pharmacological inhibition of Gal-3 with MCP was not able to prevent the increase in neither systolic BP levels nor the cardiac hypertrophy (Table 2 ). Cardiac Gal-3 expression was upregulated in SHR rats at mRNA (2.5-fold; P<0.001) and protein levels (1.8-fold; P<0.01) when compared with normotensive rats (Figure 2A) . The increase in Gal-3 levels in SHR was accompanied by enhanced levels of circulating aldosterone (1.5-fold; P<0.05; Table 2 ), as it has been previously described, 6 as well as increased circulating proinflammatory markers, such as C-reactive protein and IL-1β (Table 2) . SHR group presented an increase in CCL2 (1.7-fold, P<0.05; 1.7-fold, P<0.05) and osteopontin (2.6-fold, P<0.05; 1.6-fold, P<0.05) mRNA and protein levels, respectively ( Figure 2B ) located in the interstitial area and in CD68 cardiac inmunohistochemistry ( Figure 2C ). Hearts from SHR presented an increase in interstitial fibrosis (1.8-fold; P<0.05) accompanied by an increase in collagen type I cardiac inmunohistochemistry ( Figure 2D ). Accordingly, with these observations, cardiac levels of collagen type I (1.8-fold, P<0.001; 1.6-fold, P<0.05) and the profibrotic mediators transforming growth factor-β (1.6-fold, P<0.001; 1.3-fold, P<0.05) and connective tissue growth factor (2.6-fold, P<0.001; 1.4-fold, P<0.05) were higher in SHR than in control ones at mRNA and protein expressions, respectively ( Figure 2E ). Strong and positive correlations were found between Gal-3 mRNA levels and proinflammatory and profibrotic markers, such as CCL2, osteopontin, collagen type I, transforming growth factor-β, and connective tissue growth factor (Table 1) . MCP cotreatment was able to reduce the increase in inflammation and cardiac fibrosis in SHR. In addition, strong and positive correlations were found between cardiac inflammatory markers and fibrotic mediators showing the relationship between inflammation and fibrosis that occurs during cardiac remodeling (Table 1) .
To complete the understanding of Gal-3 in aldosteroneinduced cardiac inflammation and fibrosis, normotensive WT and Gal-3 knockout mice were infused with aldosterone in the absence of salt to avoid an increase in BP and its potential confounding effects. Any of the groups presented modifications in neither hemodynamic nor cardiac parameters. 20 Aldosterone treatment increased CCL2 (1.4-fold; P<0.05) and osteopontin (1.4-fold; P<0.05) protein levels in WT mice ( Figure 3A and 3B), whereas Gal-3 knockout mice were specifically resistant to aldosterone-induced proinflammatory marker increases (P<0.05; Figure 3A and 3B). In any of the groups studied, MMP-2 activity was not modified ( Figure 3C ). As previously published, all of these modifications induced by aldosterone were accompanied in WT mice by increased Gal-3 expression, interstitial fibrosis, and enhanced ECM components such as collagen I and collagen III, whereas Gal-3 knockout mice were specifically resistant to aldosterone-induced cardiac remodeling, as we already showed. 
Comparative Effects Between Aldosterone and Gal-3 on Proinflammatory and Profibrotic Markers in Human Cardiac Fibroblasts In Vitro
Treatment with aldosterone (10 -8 mol/L) was able to increase intracellular Gal-3 protein expression (1.5-fold; P<0.05) at 24 hours ( Figure 4A ). The presence of the MR antagonist spironolactone was able to prevent the increase in Gal-3 protein levels induced by aldosterone ( Figure 4A ) in human cardiac fibroblasts.
We next compared the effects of aldosterone and Gal-3 on inflammatory markers and ECM production in human cardiac fibroblasts. Cells treated with aldosterone presented an increase in the secretion of proinflammatory markers such as IL-6 (2.0-fold; P<0.01) and CCL2 (1.4-fold; P<0.05; Figure 4B ). Gal-3-treated cells enhanced the secretion of IL-1β (1.9-fold; P<0.01), IL-6 (2.2-fold; P<0.001), and CCL2 (1.7-fold; P<0.01; Figure 4B ). Complementary, aldosterone was able to increase ECM components such as collagen type I (2.1-fold; P<0.01), collagen type III (2.3-fold; P<0.01), and fibronectin (1.5-fold; P<0.05) but not transforming growth factor-β ( Figure 4C ). Gal-3-treated cells increased similarly collagen type I (1.9-fold; P<0.01), collagen type III (4.0-fold; P<0.001), and fibronectin (2.0-fold; P<0.01) protein levels ( Figure 4C ). Furthermore, aldosterone induced an increase in MMP-1 (1.6-fold; P<0.05), MMP-2 (1.5-fold; P<0.01), and MMP-9 (1.4-fold; P<0.05) activities ( Figure 4D ). Gal-3 induced similar 
Gal-3 Inhibition Blocked Aldosterone Proinflammatory and Profibrotic Effects in Human Cardiac Fibroblasts In Vitro
To investigate the role of Gal-3 in aldosterone effects in human cardiac fibroblasts, Gal-3 silencing was used. Gal-3 siRNA reduced significantly Gal-3 mRNA (0.9-fold; P<0.001) and protein expressions (0.5-fold; P<0.05) when compared with controls ( Figure 5A ). Aldosterone treatment did not modify Gal-3 levels in Gal-3-knocked down cells ( Figure 5A ). In Gal-3-silenced cells, aldosterone did not increase CCL2 and osteopontin at mRNA levels and IL-6 and CCL2 at protein levels ( Figure 5B ). Moreover, aldosterone did not modify collagen type I and collagen type III mRNA and protein levels, as well as fibronectin protein levels ( Figure 5C ) in Gal-3-knocked down cells. Furthermore, Gal-3 inhibition was able to block the increase in MMP-1 and MMP-2 activities induced by aldosterone ( Figure 5D ).
Discussion
The purpose of this study was to investigate the role of Gal-3 in cardiac inflammation and fibrosis and its role as a mediator of aldosterone-induced cardiac damage in vitro and in vivo. In animal models, Gal-3 pharmacological inhibition prevented cardiac inflammation and fibrosis associated with an excess of aldosterone levels independently of BP levels. In human cardiac fibroblasts, aldosterone increased Gal-3 expression via MR. Gal-3 enhanced the production and secretion of proinflammatory and profibrotic mediators. Moreover, Gal-3 inhibition blocked aldosterone-induced proinflammatory and profibrotic molecules. Thus, Gal-3 emerges as a key mediator of inflammatory response and cardiac fibrosis associated with high-aldosterone situations.
Previous studies by our group have demonstrated that Gal-3 inhibition prevented cardiac fibrosis induced by aldosterone. 20 Similar beneficial effects of Gal-3 inhibition have been reported on cardiac fibrosis, remodeling, and dysfunction in angiotensin II-treated animals independently of BP levels. 23 In aldosterone-salt-treated rats, Gal-3 inhibition with MCP blocked hypertension, normalizing BP levels. 20 Independently of hypertension, aldosterone per se has been demonstrated to promote cardiac inflammation and fibrosis, characterized by perivascular mononuclear infiltrate cells and increased adhesion markers with chemokine and cytokine expression as it has been reported. 24 The pharmacological blockade of Gal-3 and genetic disruption of Gal-3 were able to prevent the increase in inflammatory markers and in MMP activities induced by aldosterone, suggesting that Gal-3 is a novel mediator of cardiac inflammation. This effect of Gal-3 on aldosterone actions was confirmed in human cardiac fibroblasts where aldosterone and Gal-3 showed proinflammatory and profibrotic properties in cardiac fibroblasts, increasing inflammatory markers, MMP activities, and ECM components, as it has been previously published in other cell types. 19, 25 Moreover, in cardiac fibroblasts, Gal-3 silencing was able to prevent the increase in inflammatory and fibrotic markers induced by aldosterone.
SHR is characterized by structural and functional changes in the heart, 26 such as cardiac hypertrophy that is accompanied by an inflammatory process. 27, 28 However, the role of aldosterone excess in the inflammatory and fibrotic responses in this model remains poorly understood. Aldosterone and Gal-3 levels, as well as cardiac inflammation and fibrosis, were increased in SHR when compared with normotensive controls. The increase in cardiac Gal-3 levels in this experimental hypertension was also observed in a double transgenic animal model of cardiac hyperaldosteronism and systemic hypertension. 21 Gal-3 pharmacological inhibition did not affect hypertension in SHR because MCP-treated rats present similar BP levels compared with nontreated SHR. However, under hypertensive conditions, Gal-3 blockade exerted beneficial effects, diminishing cardiac inflammation and fibrosis. Thus, these results show the key role of Gal-3 in the cardiac remodeling associated with hypertension and the beneficial effects of Gal-3 pharmacological inhibition on cardiac inflammation and fibrosis, which finally could affect cardiac function and heart failure development.
In summary, Gal-3 emerges as a new molecule for regulating cardiac inflammation and fibrosis progression associated with high-aldosterone levels. This study demonstrates the beneficial effects of Gal-3 blockade in situations with highaldosterone levels, such as hypertension, representing a novel therapeutic target in cardiac inflammation and fibrosis.
Perspectives
Gal-3 inhibition blocks cardiac inflammation and fibrosis in experimental hyperaldosteronism independently of the presence of high-BP levels. More in-depth mechanistic studies would be needed to understand the mechanisms by which Gal-3 inhibition blocks aldosterone hypertensive effects. Further clinical studies are required to establish the potential therapeutic benefit of Gal-3 inhibition in hypertensive patients.
What Is New?
• Galectin-3 (Gal-3) mediates aldosterone-induced cardiac inflammation and fibrosis.
• Gal-3 blockade protects against cardiac inflammation and fibrosis in hypertension.
• Gal-3 could be one mechanistic connection between cardiac inflammation and fibrosis.
What Is Relevant?
• Gal-3 is a new biomarker, recommended for the management of heart failure (American Heart Association 2013 Guidelines), reflecting disease severity and prognosis.
• This study provides a new pharmacological agent that attenuates cardiac inflammation and fibrosis in situations with high-aldosterone levels such as hypertension.
Summary
Gal-3 blockade inhibits cardiac inflammation and fibrosis in hypertensive rats. Genetic disruption and pharmacological inhibition of galectin-3 effectively block cardiac inflammation and fibrosis induced by aldosterone.
